PSMA ADC in treatment of mCRPC post-chemo and post-abiraterone and/or enzalutamide

Data from an open-label Phase II trial of PSMA ADC — a fully human IgG1 antibody conjugated to monomethyl auristatin E (MMAE) — suggests that this agent has activity in treatment of metastatic, castration-resistant prostate cancer (mCRPC) patients who have already progressed on abiraterone acetate and/or enzalutamide. … READ MORE …

Current and “next generation” treatments for mCRPC: a new review

For those actually dealing with metastatic, castration-resistant prostate cancer (mCRPC) or who think they may be faced with dealing with this in the near future, there is a new review of current and future treatments for mCRPC available on the Medscape Oncology web site. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Prostvac Phase III trial results in mCRPC “by early 2017″

According to a Reuters report issued early this morning, the CEO of Barvarian Nordic has stated publicly that the company expects results of Phase III trials of Prostvac VF in men with metastatic, castration-resistant prostate cancer (mCRPC) by early 2017 or perhaps earlier. … READ MORE …

Prostvac + ipilimumab shows promise in management of mCRPC

Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Metformin + BI2536 may have significant activity in mCRPC

According to an new article in the Journal of Biological Chemistry, the combination of metformin with a polo-like kinase 1 (Plk1) inhibitor known currently as BI2536 appears to be able to suppress the spread of prostate cancer that resists all other available treatments. … READ MORE …

Efavirenz not effective in the treatment of mCRPC

Some time ago a group of French researchers initiated a Phase II trial of efavirenz (Sustiva®) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,261 other followers